Ticiana De Francesco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ticiana De Francesco has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Iqbal Ike K. Ahmed
Prism Eye Institute, Mississauga, Canada
10 shared publications Iqbal Ike K. Ahmed
Salt Lake City, Utah, and Ontario, Canada
6 shared publicationsIqbal Ike K Ahmed
John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA
4 shared publicationsEric Mikula
3 shared publications- Amanda de Paula Pessôa Paula Botelho2 shared publications
Amer F. Alsoudi
Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (6) , 1458-1468
Intermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma
- 7 September 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (6) , 1458-1468
Open AccessIntermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-14
Peripheral Iris Cerclage in Angle Closure Glaucoma: A Retrospective Pilot Study
Purpose: To describe a novel surgical technique using peripheral iris cerclage (PIC) and evaluate clinical and anatomical outcomes in eyes with angle-closure glaucoma (ACG). Methods: Single-center retrospective pilot study of 8 consecutive eyes (7 patients) with ACG at high risk of recurrence undergoing peripheral iris cerclage (2010– 2025), with adjunctive procedures. Primary outcomes were postoperative Shaffer angle grade and peripheral anterior synechiae (PAS). Secondary outcomes included surgical success, intraocular pressure (IOP), and glaucoma medication use. Surgical success was defined as IOP ≤ 18 mmHg with ≥ 20% reduction from baseline, without clinical hypotony (IOP < 6 mmHg accompanied by ≥ 2-line loss of visual acuity from baseline). Eyes that underwent surgical revision, reoperation or developed no light perception vision were classified as failures. Complete success required no glaucoma medications; qualified success permitted glaucoma medications. Results: Median Shaffer angle grading (interquartile range [IQR]) increased significantly from 0 (0– 0) to 3 (3– 3) (P=0.01), and PAS also significantly decreased in all eyes (P=0.03), with 6 eyes (75%) demonstrating no PAS. Postoperative imaging demonstrated relative thinning of the peripheral iris and widening of the angle. Median IOP decreased from 33.5 (31.2– 43.5) mmHg to 12.0 (10– 15) mmHg (p=0.01) and medication classes decreased from 4 (4– 4) to 2 (1– 3) (p=0.04). Two eyes (25.0%) achieved complete success, while 7 eyes (87.5%) achieved qualified success. No intraoperative complications occurred. One patient required secondary glaucoma surgery. Conclusion: Peripheral iris cerclage was associated with sustained angle widening, favorable PAS outcomes, and substantial IOP reduction in this pilot series. This technique may serve as a useful adjunct in the surgical management of glaucoma, particularly in ACG eyes with flaccid iris tone, a high or thick iris insertion, and risk of recurrent synechiae.
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-14
Open AccessPeripheral Iris Cerclage in Angle Closure Glaucoma: A Retrospective Pilot Study
Purpose: To describe a novel surgical technique using peripheral iris cerclage (PIC) and evaluate clinical and anatomical outcomes in eyes with angle-closure glaucoma (ACG). Methods: Single-center retrospective pilot study of 8 consecutive eyes (7 patients) with ACG at high risk of recurrence undergoing peripheral iris cerclage (2010– 2025), with adjunctive procedures. Primary outcomes were postoperative Shaffer angle grade and peripheral anterior synechiae (PAS). Secondary outcomes included surgical success, intraocular pressure (IOP), and glaucoma medication use. Surgical success was defined as IOP ≤ 18 mmHg with ≥ 20% reduction from baseline, without clinical hypotony (IOP < 6 mmHg accompanied by ≥ 2-line loss of visual acuity from baseline). Eyes that underwent surgical revision, reoperation or developed no light perception vision were classified as failures. Complete success required no glaucoma medications; qualified success permitted glaucoma medications. Results: Median Shaffer angle grading (interquartile range [IQR]) increased significantly from 0 (0– 0) to 3 (3– 3) (P=0.01), and PAS also significantly decreased in all eyes (P=0.03), with 6 eyes (75%) demonstrating no PAS. Postoperative imaging demonstrated relative thinning of the peripheral iris and widening of the angle. Median IOP decreased from 33.5 (31.2– 43.5) mmHg to 12.0 (10– 15) mmHg (p=0.01) and medication classes decreased from 4 (4– 4) to 2 (1– 3) (p=0.04). Two eyes (25.0%) achieved complete success, while 7 eyes (87.5%) achieved qualified success. No intraoperative complications occurred. One patient required secondary glaucoma surgery. Conclusion: Peripheral iris cerclage was associated with sustained angle widening, favorable PAS outcomes, and substantial IOP reduction in this pilot series. This technique may serve as a useful adjunct in the surgical management of glaucoma, particularly in ACG eyes with flaccid iris tone, a high or thick iris insertion, and risk of recurrent synechiae.
- 15 June 2026
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 9 (4) , 357-359
The Flip Sides of Interventional Glaucoma
- 15 June 2026
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 9 (4) , 357-359
The Flip Sides of Interventional Glaucoma
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-16
Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study
Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and adverse event profile of Xen63 gel stent compared to the Preserflo microshunt. Methods: Retrospective, multicenter, two-arm cohort study comparing 65 eyes undergoing standalone Xen63 implantation and 75 eyes undergoing standalone Preserflo implantation, all with intraoperative mitomycin C (MMC). Primary outcome was complete success, defined as all of the followings: 1) no two consecutive IOP readings > 17mmHg, 2) ≥ 20% IOP reduction from baseline; 3) no clinical hypotony (IOP < 6 mmHg associated with loss of ≥ 2 lines of vision); and 4) no use of glaucoma medications. Secondary outcomes included success at different IOP cut offs, qualified success (allowing medications), change in IOP, medications, complications, interventions, and re-operations. Results: At 12 months, complete success was achieved in 61.5% of eyes in the Xen63 group and 73.9% in the Preserflo group (p = 0.13). Postoperative complications were more frequent in the Xen63 group compared with the Preserflo group (61.5% vs. 29.3%, p = 0.0002). Postoperative interventions were required at similar rates between groups (Xen63 30.8% vs. Preserflo 28.0%, p = 0.85); however, reoperations were performed more frequently in the Xen63 group (16.9% vs. 4.0%, p = 0.01). Non-Caucasian ethnicity was associated with an increased risk of surgical failure (HR 2.57; 95% CI, 1.26– 5.23). Conclusion: Both devices achieved comparable success rates, median IOP reduction, and postoperative medication burden; however, the Xen63 group experienced a higher rate of complications and reoperations.
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-16
Open AccessComparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study
Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and adverse event profile of Xen63 gel stent compared to the Preserflo microshunt. Methods: Retrospective, multicenter, two-arm cohort study comparing 65 eyes undergoing standalone Xen63 implantation and 75 eyes undergoing standalone Preserflo implantation, all with intraoperative mitomycin C (MMC). Primary outcome was complete success, defined as all of the followings: 1) no two consecutive IOP readings > 17mmHg, 2) ≥ 20% IOP reduction from baseline; 3) no clinical hypotony (IOP < 6 mmHg associated with loss of ≥ 2 lines of vision); and 4) no use of glaucoma medications. Secondary outcomes included success at different IOP cut offs, qualified success (allowing medications), change in IOP, medications, complications, interventions, and re-operations. Results: At 12 months, complete success was achieved in 61.5% of eyes in the Xen63 group and 73.9% in the Preserflo group (p = 0.13). Postoperative complications were more frequent in the Xen63 group compared with the Preserflo group (61.5% vs. 29.3%, p = 0.0002). Postoperative interventions were required at similar rates between groups (Xen63 30.8% vs. Preserflo 28.0%, p = 0.85); however, reoperations were performed more frequently in the Xen63 group (16.9% vs. 4.0%, p = 0.01). Non-Caucasian ethnicity was associated with an increased risk of surgical failure (HR 2.57; 95% CI, 1.26– 5.23). Conclusion: Both devices achieved comparable success rates, median IOP reduction, and postoperative medication burden; however, the Xen63 group experienced a higher rate of complications and reoperations.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-2
A Systematic and Narrative Review of Safety and Complications in Minimally Invasive Glaucoma Surgery (MIGS) Between 2014–2024 [Letter]
Introduction: Earlier intervention in glaucoma has been suggested to slow disease progression and preserve visual function and quality of life. Consequently, minimally invasive glaucoma surgery (MIGS) is increasingly used in mild-to-moderate glaucoma. Although numerous techniques and devices are available, their comparative efficacy remains debated: most procedures lower intraocular pressure to the mid-teens in primary open-angle glaucoma, but without clear evidence of superiority. As these surgeries are now offered to younger, otherwise healthy patients, safety has therefore become a central criterion in technique selection. Methods: This PRISMA-based systematic review analyzed safety outcomes from peer-reviewed studies of the main MIGS procedures published between 2014 and 2024. Five databases were searched using current and historical device names. Non-clinical studies, case series, and nonstandard techniques were excluded from quantitative analysis but retained qualitatively to capture rare events. A total of 401 studies, representing 39,381 eyes and 68,917 eye-years of follow-up, were included. Highest reported and weighted mean complication rates were calculated by procedure type. Results: Safety profiles varied. Trabecular bypass implants and ab interno canaloplasty were associated with low rates of serious adverse events and minimal anatomical disruption. Suprachoroidal devices carried higher risks of hypotony, inflammation, and malposition. Across all categories, chronic changes to angle anatomy and occasionnal re-interventions highlighted the potential for long-term sequelae, with endothelial cell loss emerging as a key concern for certain procedures.However, heterogeneity in definitions and reporting limited comparability. Common events such as hyphema and IOP spikes were inconsistently documented, while late complications like endothelial cell loss or peripheral anterior synechiae were often overlooked. This underreporting risks conflicting conclusions and undermines comparisons. Conclusion: For patients with mild, stable disease or those undergoing opportunistic combined surgery, tissue-sparing procedures with the lowest observed complication rates may be preferable. Standardized definitions, long-term follow-up, and harmonized safety reporting are becoming essential.
- 1 April 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-2
Open AccessA Systematic and Narrative Review of Safety and Complications in Minimally Invasive Glaucoma Surgery (MIGS) Between 2014–2024 [Letter]
Introduction: Earlier intervention in glaucoma has been suggested to slow disease progression and preserve visual function and quality of life. Consequently, minimally invasive glaucoma surgery (MIGS) is increasingly used in mild-to-moderate glaucoma. Although numerous techniques and devices are available, their comparative efficacy remains debated: most procedures lower intraocular pressure to the mid-teens in primary open-angle glaucoma, but without clear evidence of superiority. As these surgeries are now offered to younger, otherwise healthy patients, safety has therefore become a central criterion in technique selection. Methods: This PRISMA-based systematic review analyzed safety outcomes from peer-reviewed studies of the main MIGS procedures published between 2014 and 2024. Five databases were searched using current and historical device names. Non-clinical studies, case series, and nonstandard techniques were excluded from quantitative analysis but retained qualitatively to capture rare events. A total of 401 studies, representing 39,381 eyes and 68,917 eye-years of follow-up, were included. Highest reported and weighted mean complication rates were calculated by procedure type. Results: Safety profiles varied. Trabecular bypass implants and ab interno canaloplasty were associated with low rates of serious adverse events and minimal anatomical disruption. Suprachoroidal devices carried higher risks of hypotony, inflammation, and malposition. Across all categories, chronic changes to angle anatomy and occasionnal re-interventions highlighted the potential for long-term sequelae, with endothelial cell loss emerging as a key concern for certain procedures.However, heterogeneity in definitions and reporting limited comparability. Common events such as hyphema and IOP spikes were inconsistently documented, while late complications like endothelial cell loss or peripheral anterior synechiae were often overlooked. This underreporting risks conflicting conclusions and undermines comparisons. Conclusion: For patients with mild, stable disease or those undergoing opportunistic combined surgery, tissue-sparing procedures with the lowest observed complication rates may be preferable. Standardized definitions, long-term follow-up, and harmonized safety reporting are becoming essential.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Intermediate Outcomes of a Novel Flat Glaucoma Drainage Device in Uncontrolled Primary Open Angle Glaucoma
To evaluate the intraocular pressure (IOP) lowering effect and adverse event profile of the Implante Plano Miranda (IPM), a novel flat glaucoma drainage device. Prospective, single-arm, open-label Phase II clinical trial including 24 eyes with uncontrolled primary open-angle glaucoma (POAG) despite maximal tolerated medical therapy, undergoing standalone IPM implantation with adjunctive Mitomycin-C (MMC). Primary outcome was the proportion of eyes achieving surgical success, defined by: ≥ 20% IOP reduction from baseline on same or fewer medications without clinical hypotony or reoperation. Secondary outcomes included changes in IOP, medication burden, endothelial cell density (ECD), and adverse events. Patients were followed for 12 months. At 12 months, surgical success was achieved in 79.5% of eyes. Median IOP decreased from 24.0 mmHg (IQR 24–26) preoperatively to 14.0 mmHg (IQR 12–17) at one year (p < 0.0001), representing a 41.6% reduction. Median glaucoma medications decreased from 4 (IQR 3–4) to 1 (IQR 0–3) (p < 0.0001). ECD remained stable (baseline 1,671.98 ± 570.75 vs. 12 months 1,684.37 ± 549.25 cells/mm2; p = 0.797). Minor adverse events occurred in 29.1% of eyes; no serious complications or reoperations were reported. The IPM was associated with significant IOP reduction and decreased medication use at one year. No serious safety events were observed during the 12-month follow-up. Given the small sample size and single-arm design, larger controlled studies with longer follow-up are necessary to better define the safety and efficacy profile of this device.
- 1 April 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Open AccessIntermediate Outcomes of a Novel Flat Glaucoma Drainage Device in Uncontrolled Primary Open Angle Glaucoma
To evaluate the intraocular pressure (IOP) lowering effect and adverse event profile of the Implante Plano Miranda (IPM), a novel flat glaucoma drainage device. Prospective, single-arm, open-label Phase II clinical trial including 24 eyes with uncontrolled primary open-angle glaucoma (POAG) despite maximal tolerated medical therapy, undergoing standalone IPM implantation with adjunctive Mitomycin-C (MMC). Primary outcome was the proportion of eyes achieving surgical success, defined by: ≥ 20% IOP reduction from baseline on same or fewer medications without clinical hypotony or reoperation. Secondary outcomes included changes in IOP, medication burden, endothelial cell density (ECD), and adverse events. Patients were followed for 12 months. At 12 months, surgical success was achieved in 79.5% of eyes. Median IOP decreased from 24.0 mmHg (IQR 24–26) preoperatively to 14.0 mmHg (IQR 12–17) at one year (p < 0.0001), representing a 41.6% reduction. Median glaucoma medications decreased from 4 (IQR 3–4) to 1 (IQR 0–3) (p < 0.0001). ECD remained stable (baseline 1,671.98 ± 570.75 vs. 12 months 1,684.37 ± 549.25 cells/mm2; p = 0.797). Minor adverse events occurred in 29.1% of eyes; no serious complications or reoperations were reported. The IPM was associated with significant IOP reduction and decreased medication use at one year. No serious safety events were observed during the 12-month follow-up. Given the small sample size and single-arm design, larger controlled studies with longer follow-up are necessary to better define the safety and efficacy profile of this device.
- Open Access
- 2 February 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (3) , 591-600
One-year outcomes of an ab externo sibs microshunt in combination with phacoemulsification
- 2 February 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (3) , 591-600
Open AccessOne-year outcomes of an ab externo sibs microshunt in combination with phacoemulsification
- 2 January 2026
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 9 (3) , 295-301
A Large-Scale Cohort Analysis of Topical Prostaglandin Analog Use and Pseudophakic Cystoid Macular Edema Following Cataract Surgery
- 2 January 2026
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 9 (3) , 295-301
A Large-Scale Cohort Analysis of Topical Prostaglandin Analog Use and Pseudophakic Cystoid Macular Edema Following Cataract Surgery
- 14 May 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 277, 169-183
Glaucoma Surgery Comparison: SIBS Microshunt Versus Gelatin 45 µm Microstent Versus Trabeculectomy as Primary Surgical Interventions
- 14 May 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 277, 169-183
Glaucoma Surgery Comparison: SIBS Microshunt Versus Gelatin 45 µm Microstent Versus Trabeculectomy as Primary Surgical Interventions
- Open Access
- 3 February 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 5 (4) , 100727
Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement
- 3 February 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 5 (4) , 100727
Open AccessBio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement